Search results for: NICE
Filter search results
Recent Statistics on Orphan Approvals in Scotland and England
23 August 2011
…5 Average across indications 29 43 Minimum 1 2 50 percentile 12 25 Maximum 179 179 NICE Decisions on OMPs[*] NICE has assessed nine indications for orphan conditions: azacitidine for…
Valuing Health at the End of Life: Public Preferences
13 October 2011
In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that extend life at the…
The Expanding Value Footprint of Oncology Treatments
13 May 2014
…disease stage, treatment stage, treatment regimen, or patient population or subpopulation. The decisions of three entities were included in the study: the Haute Autorité de Santé (HAS) in France, NICE…
OHE Occasional Paper Critiques the Claxton et al. £13,000 per QALY Estimate
24 February 2015
…Last week, the journal Health Technology Assessment published the results of a study exploring methods for the estimation of the NICE cost-effectiveness threshold (Claxton et al., 2015). In this study,…
An Issues Panel: Developing Cost Effectiveness for Decision Making: What can be Learnt from “Value Based Pricing”?
29 July 2015
…NICE Decision Support Unit, University of Sheffield. It included the following contributions: Adrian Towse presented “Reflections on Value Based Pricing/Assessment” with an overview of the main elements of the Value…
How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.
26 March 2020
…contracting for new antibiotics. It analyses UK (NICE and NHSE) plans to introduce a subscription model (delinking use of new antibiotics from payments for making the products available) and suggests…
Caroline Bregman
30 June 2023
Caroline is a Principal Scientific adviser within the NICE scientific Advice and NICE International teams. She is involved in a range of scientific advice projects and parallel scientific advice procedures…
Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
16 January 2024
…National Institute for Health and Care Excellence (NICE) and NHS England trialled a volume-delinked subscription-type model for two antibiotics for severe infections resistant to the last line of antibiotics (NICE,…
Unlocking the broader value of biologic therapies through biosimilar-enabled access and repositioning
23 September 2026
…C) illustrate all five framework channels across five systems: NICE (England), PHARMAC (New Zealand), PBAC (Australia), TLV (Sweden) and CMS (US). In-depth modelling of two cases demonstrates the quantitative value…